Compare JPMorgan Chase & Co (JPM) vs Novartis AG (NVS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
JPMorgan Chase & Co vs Novartis AG — how do they compare? JPMorgan Chase & Co trades at $332.99 (market cap $880.98B), while Novartis AG trades at $143.75 (market cap $268.57B). The key difference: JPMorgan Chase & Co is far larger — about 3.3× Novartis AG's market cap, and Novartis AG pays the higher dividend (3.31%). Which is the better fit depends on your goals — on Pluang, investors hold JPMorgan Chase & Co for 127 Days and Novartis AG for 82 Days on average.
| JPM | NVS | |
|---|---|---|
Market Cap | $880.98B | $268.57B |
Volume | 7,721,661 | 1,532,573 |
Sector | Financials | Health |
52-Week High | $365.18 | $168.62 |
52-Week Low | $282.84 | $121.80 |
Typical Hold Time | 127 Days | 82 Days |
Enterprise Value | $1.82T | $309.89B |
Dividend Yield | 1.99% | 3.31% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
JPMorgan Chase & Co. (JPM) trades at $331.42, up 0.56% today, with a bearish technical signal but strong fundamentals. Recent earnings beat expectations in Q1 and Q2 2026, with revenue growing to $181.85B in 2025. The stock shows a P/E of 14.2 and ROE of 18.43%, supported by a 'Moderate Buy' analyst consensus and a $373.18 price target.
Outlook remains positive due to robust profitability and institutional confidence, though risks include geopolitical tensions and cybersecurity threats highlighted in recent news. The stock offers value with upside potential, but investors should monitor cash flow trends and macroeconomic headwinds.
NVS trades at $143.11, down 0.12% on the day, with a bearish technical signal and mixed earnings history including a recent Q1 2026 miss. The company maintains strong profitability with a 22.5% net income margin and 30.55% ROE, while recent news highlights a major $7.8B licensing deal with China's Abogen and ongoing investor scrutiny following clinical trial setbacks.
The outlook is cautious; analyst consensus is a Hold with a $146 price target, but risks include pipeline disappointments and M&A execution. Upside hinges on successful drug launches and deal integration, while downside stems from competitive pressures and regulatory challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About JPMorgan Chase & Co
JPMorgan Chase & Co. provides global financial services and retail banking. The Company provides services such as investment banking, treasury and securities services, asset management, private banking, card member services, commercial banking, and home finance. JP Morgan Chase serves business enterprises, institutions, and individuals.
Read more on JPM →About Novartis AG
Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →
